Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma
Protocol ID
ANBL1821
Disease (Sub Disease)
Solid tumours (Neuroblastoma)
Diagnosis Stage
Relapse/refractory
Location
NSW, QLD, VIC, WA, NZ
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
Trial Status
Open
Sites
Perth Children's Hospital
Queensland Children's Hospital
The Children's Hospital at Westmead
Sydney Children's Hospital
Royal Children's Hospital
Christchurch Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
1 Year and older
International registry ID's
NCT03794349
Back to Registry
Study Title A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma
Protocol ID ANBL1821
Disease (Sub Disease) Solid tumours (Neuroblastoma)
Diagnosis Stage Relapse/refractory
Location NSW / QLD / VIC / WA / NZ
Sponsor Children's Oncology Group
Collaborators National Cancer Institute (NCI)
Links https://clinicaltrials.gov/ct2/show/NCT03794349
Trial Status Open
Trial Open Date 28/05/2019
Sites Perth Children's Hospital / Queensland Children's Hospital / The Children's Hospital at Westmead/ Sydney Children's Hospital / Royal Children's Hospital / Christchurch Hospital / Starship Hospital
Study Type Treatment
Phase Phase 2
Age Eligibility 1 Year and older
International registry ID's NCT03794349